The aim of this study was to determine the relationship between the neuroprotective effect of SM-20220 (N-(aminoiminomethyl)-1-methyl-1H-indole-2-carboxamide methanesulfonate) and the timing of its administration in an experimental stroke model. Two hours of occlusion followed by 22 h of perfusion of the left middle cerebral artery (MCA) was performed by inserting a nylon thread into the MCA to occlude it, and pulling the thread to initiate reperfusion. Intravenous infusion of SM-20220 for 1 h reduced the infarct volume at doses of 0.2-0.8 mg/kg in a dose-dependent manner without causing changes in the systemic arterial blood pressure or blood gases, when SM-20220 administration was started 1 h after the onset of occlusion. Administration of SM-20220 at a dose of 0.4 mg/kg also reduced the edema formation induced by ischemia. In contrast, SM-20220 failed to reduce the infarction, even at 1.6 mg/kg, when administration was started 2 h after the onset of occlusion. Thus, the therapeutic time window of SM-20220 for this transient MCA occlusion model is 1 h. Daily administration of SM-20220 (0.4 mg/kg) for the 7 d following 1.5 h of middle cerebral artery occlusion reduced the infarct volume with statistical significance ( pϽ0.05), showing that SM-20220 did not merely delay but prevented ischemic damage.
, and Ca 2ϩ ions. [1] [2] [3] [4] This phenomenon is thought to play a key role in ischemic damage. 5) The Na ϩ /H ϩ exchanger (NHE) is a mammalian plasma membrane glycoprotein that mediates the exchange of intracellular H ϩ for extracellular Na ϩ with a 1 : 1 stoichiometry and thus influences the regulation of cell volume and pHi. 6) In the heart, many reports have demonstrated that ischemia-reperfusion activates the NHE, and such activation causes an increase in the intracellular Na ϩ and a secondary increase in Ca 2ϩ via Na ϩ /Ca 2ϩ exchanger activation (for review, see ref. 7) . A similar series of events is believed to occur in the ischemic brain. Indeed, blocking NHE activity prevents ischemic injury in gerbil hippocampal neurons 8) and inhibits the release of the excitotoxic amino acids glutamate and aspartate, which can induce the death of susceptible neurons. 9 ) SM-20220 (N-(aminoiminomethyl)-1-methyl-1H-indole-2-carboxamide methanesulfonate), a compound discovered by Sumitomo Pharmaceuticals, inhibits the NHE. In an early study, SM-20220 attenuated the tissue Na ϩ increase and provided neuroprotection against ischemic injury in the rat. 10) Furthermore, SM-20220 improved the neurological outcome and survival rate in gerbil stroke models. 11) These results suggest that the NHE inhibitor may represent a new class of drugs for the treatment of ischemic brain injury. In this study, we used a rat transient stroke model to investigate the relationship between the neuroprotective effect of SM-20220 and the timing of its administration.
MATERIALS AND METHODS

Transient Middle Cerebral Artery (MCA) Occlusion
Model All procedures related to the use of animals in the present study were reviewed and approved by the Institutional Animal Care and Use Committee at Sumitomo Pharmaceuticals Research Division and were in compliance with the 'Guiding Principles for the Care and Use of Laboratory Animals' approved by the Japanese Pharmacological Society. The surgical procedures were as described previously. 10) Briefly, male Wistar rats (Japan SLC, Hamamatsu, Japan) weighing about 200-240 g were used. All surgical procedures were performed under halothane anesthesia (induction at 4% and maintenance at 1% in 70% N 2 O/30% O 2 ), and core body temperature was maintained at 37°C with a heating pad (BWT-100, Bioresearch Center, Nagoya, Japan) during the surgical procedure. The right femoral vein was cannulated with a polyethylene catheter (PE50, Becton-Dickinson, NJ, U.S.A.) to allow drug administration. After median incision of the neck skin, the left external carotid artery and main carotid artery were occluded. Transient focal ischemia was induced by occluding the left MCA using an intraluminal suture technique.
12) A 16-mm length of 4-0 nylon thread precoated with silicon (outer diameter 0.45 mm) (KE45 W, Shinetsu, Tokyo, Japan) was inserted from the lumen of the internal carotid artery to occlude the left MCA at its origin. After surgery, anesthesia was discontinued and the extent of paresis of the right forelimb was used to assess ischemic insult. Reperfusion was established by pulling out the occluding thread 1.5 or 2 h after the onset of MCA occlusion.
Measurement of Infarct Size
To measure the infarct size, rats were decapitated 22 h or 7 d after the onset of reperfusion, and five coronal sections of 2-mm thickness (3 mm anterior-5 mm posterior to the bregma) were prepared and stained with 2,3,5-triphenyl tetrazolium chloride (Nacalai Tesque, Kyoto, Japan) solution. 12) Photographs of the slices were taken. The infarcted area of each slice was identified by its failure to be stained with 2,3,5-triphenyl tetrazolium chloride. The infarcted area was quantified with a computerized image analysis system (NIH Image) and expressed as a per-centage of the area of the left hemisphere for each coronal section. The infarct volume was calculated by integration of the infarct areas and the areas of the left hemisphere that were determined for the five coronal sections.
Measurement of Arterial Blood Pressure, Gases, and pH In some animals, a femoral artery was cannulated to directly and continuously measure the systemic arterial blood pressure with a pressure transducer (P10EZ, Nihon Kohden, Osaka, Japan) attached to a blood-pressure amplifier (AP-641G, Nihon Kohden) and to sample blood for the analysis of blood gases and pH using I-STAT (Fuso Chemicals, Osaka, Japan).
Measurement of Cerebral Water Content
To measure the brain water content, rats were decapitated 4 h after the onset of reperfusion and the left hemisphere of the occluded MCA territory was cut into 4-mm-thick slices (1 mm anterior-3 mm posterior to the bregma).
10) The water content was determined by the dry-weight method.
13)
Experimental Protocol The experimental protocol is shown in Fig. 1 . SM-20220 was dissolved in 8% polyethylene glycol 400 (w/v) to 0.4 mg/ml and diluted with the same solution to 0.04, 0.08, 0.16, and 0.32 mg/ml. The diluted SM-20220 or just the solution as vehicle was given as an intravenous infusion (5 ml/kg/h) for 1 h using an infusion pump (model 100, KD Scientific, U.S.A.).
For the first experiment, the administration of SM-20220 or vehicle was started 1 h after the onset of occlusion, and physiological variables were measured before surgery, before drug administration, and 30 min after the onset of reperfusion; the infarct size was measured 22 h after the onset.
For the second experiment, administration of SM-20220 or vehicle was started immediately after reperfusion, and infarct size was measured 22 h after the onset.
For the third experiment, the administration of SM-20220 or vehicle was started 1 h after the onset of occlusion, and cerebral water content was measured 4 h after the onset.
For the fourth experiment, SM-20220 (0.4 mg/kg) or vehicle was given as an intravenous bolus injection 1 h after the onset of occlusion and then injected once daily for the following 6 d. Infarct size was measured 7 d after the onset of reperfusion.
Statistical Analysis Results were expressed as the mean ϮS.E.M. of n observations. Statistical analyses were performed with the Statistical Analysis System (release 6.12, SAS institute Inc., Cary, NC, U.S.A.). To assess physiological parameters, the significant differences among multiple groups were calculated using ANOVA. The significant difference between two groups was calculated with the F-test followed by Student's t-test or Welch's test. The significant differences among the sham-operated, vehicle, and SM-20220 treatment groups were calculated using Tukey-Kramer's multiple comparison. The significant differences between dose 0 (vehicle) and the SM-20220 treatment groups were calculated using Williams' multiple comparison.
14) The significant differences for the number of times SM-20220 was administered, between groups that received drug 0 (vehicle), 1, and 7 times, was calculated by Dunnett's multiple comparison. Differences among means were considered significant when pϽ0.05.
RESULTS
Effect on Infarct Size of a Single Administration
Twenty-two hours after reperfusion, a large infarct was formed in the left MCA territory. The MCA occlusion model, where ischemia is induced by the intraluminal insertion of a suture, is one of the major methods used to evaluate the pathophysiology of cerebral ischemia 15) and potential therapeutic intervention. However, the size of the ischemic injury produced by this technique can vary considerably. 16) To avoid this shortcoming, we modified this model to be severely ischemic by using a silicon-coated suture. 17) When SM-20220 was administered 1 h after the onset of occlusion, it reduced the infarcted area in all five sections (Fig. 2a) and the infarct volume in a dose-dependent manner (pϽ0.01 by linear regression analysis, Fig. 2b ). For the infarct volume, this effect was statistically significant in the range of 0.4-0.8 mg/kg and was nearly at its maximum at a dose of 0.4 mg/kg (Fig. 2b) . At 0.4 mg/kg, SM-20220 reduced the infarct size in sections taken at 3 mm anterior, 1 mm posterior, and 5 mm posterior to the bregma by about 42, 25, and 34%, respectively.
On the other hand, when administration was started immediately after reperfusion, 2 h after the onset of occlusion, SM-20220 failed to reduce the infarct size, even at 1.6 mg/kg (Fig. 3) .
In these experiments, the physiological variables before the operation were within the normal range and there were 768 Vol. 24, No. 7 no significant differences in any of the parameters among the vehicle and SM-20220 groups (Tables 1, 2) . At the dosages used in our experiment, SM-20220 did not affect mortality or hemorrhage rates (data not shown).
Effect on Cerebral Edema of a Single Administration Transient MCA occlusion induced a significant increase in water content in the MCA territory (sham-operated group, 79.3Ϯ0.1%; MCA occlusion and vehicle treatment group, 82.6Ϯ0.2%; pϽ0.01; Fig. 4 ). The administration of SM-20220 at a dose of 0.4 mg/kg, when administration was started 1 h after the onset of occlusion, significantly reduced the increase in cerebral water content induced by ischemia (81.8Ϯ0.2%, pϽ0.05 , Fig. 4) ; however, the cerebral water content in the SM-20220 treatment group was still higher than in the sham-operated group.
Effect on Infarct Size of Multiple Administration To ensure that SM-20220 did not merely delay but actually pre- SM-20220 was intravenously administered as a continuous infusion for 1 h, beginning 2 h after the onset of occlusion. Each value represents the meanϮS.E.M. of 4 animals. There were no significant differences among the groups by ANOVA. vented ischemic damage, we evaluated its effect on the infarct size 1 week after occlusion. When the MCA was occluded for 2 h, almost all of the animals were dead within a week; therefore, we used a 1.5-h occlusion model. One week after the onset of reperfusion, the infarcted brain was scarred, and the left hemisphere had shrunk about 10% compared with the right hemisphere. A single administration of SM-20220 significantly reduced the area of the cerebral infarction, and the reduction was statistically significant for slices taken at 3 and 5 mm posterior to the bregma (pϽ0.05, respectively, Fig. 5a ), but the infarcted volume showed no statistical significance (Fig. 5b) .
In contrast, multiple administrations of SM-20220 (once daily over the 7 d following surgery) significantly reduced the infarct volume by about 80% ( pϽ0.05, Fig. 5b) .
Body weight decreased with time after reperfusion, but there was no significant difference among the groups (Table  3 ). In another set of experiments, multiple administrations of SM-20220 (10 mg/kg/d) did not induce pathological changes in any tissues in non-operated rats (data not shown).
DISCUSSION
It is hypothesized that abnormal kinetics of ions such as H ϩ , Na ϩ , and Ca 2ϩ in brain cells are involved in the pathophysiology of ischemic cerebrovascular damage, 5) and this alteration in ion kinetics has been documented by many workers including us. 2, 10, 18, 19) Our previous study showed that SM-20220 prevented the infarction in a rat transient MCA occlusion model 10, 11) ; however, the relationship between the timing of drug administration and its beneficial effects was not clear. In the present study, we investigated the dependence of the effect of SM-20220 on infarct size on the dose and on the timing of drug administration.
SM-20220 reduced the infarct size in a dose-dependent manner when administration was started 1 h after the onset of occlusion. This effect was nearly at its maximum at a dose of 0.4 mg/kg. SM-20220 had a stronger effect on the reduction of infarct size in the peripheral ischemic region than in the central ischemic region. In a preliminary study, in which infarct size was evaluated using hematoxylin-eosin staining, SM-20220 appeared to reduce the infarct size without preventing neuronal cell death at the ischemic core (data not shown). These results indicate that SM-20220 prevents cell damage in the penumbra of the ischemic region rather than in the central area of damage. Moreover, SM-20220 reduced edema formation. There is a hypothesis that glial swelling and brain edema are caused by the activation of the NHE in cerebral ischemia. 20) In stroke patients, a contributory cause of early death in cortical infarcts is believed to be edema around the ischemic lesion, leading to transtentorial herniation, 21) and this condition is associated with an 80% mortality. 22) Therefore, the ability of SM-20220 to reduce edema formation is a very beneficial property for its therapeutic efficacy.
The protective effect of SM-20220 was attenuated when administration was started 2 h after occlusion. The therapeutic time window is one of the most important factors in clinical therapy. [23] [24] [25] pathological progression is observed in each experimental ischemic model and in individual human stroke cases, [23] [24] [25] but new drugs to be used as therapeutic agents in acute stroke are required to show beneficial efficacy in humans when administered more than 3 to 6 h after stroke onset. 23) In experimental stroke models, the infarct size is proportional to the duration of occlusion, and the threshold of MCA occlusion duration that produces maximal infarction is between 90 and 120 min. 26) Also, 2 or 3 h of occlusion followed by reperfusion induces a similar-sized cerebral infarction as does permanent occlusion. 27, 28) It may be that the cerebral tissue had already received irreversible damage by 2 h after the onset of occlusion in our model. The reported therapeutic time windows for successful experimental reperfusion when treating with 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo quinoxaline 29) or with lubeluzole, 26) a selective a-amino-3-hydroxy-5-methyllisoxazole-4-propionate antagonist and glutamate release inhibitor, are 1.5 h and 30 min, respectively. Lubeluzole shows beneficial efficacy in clinical cases. 30) These results suggest that NHE inhibitors have beneficial efficacy that is as good as other neuroprotective compounds.
Although the administration of a single dose of SM-20220 did not reduce infarct volume significantly, significant reduction was seen with multiple administrations. Nonetheless, the additive effect of the multiple administrations was not strong. It is possible that the neuroprotective effect of a single administration of SM-20220 involves a delay in the spread of ischemic damage. On the other hand, multiple administrations of SM-20220 may not merely delay but actually prevent ischemic damage. The effect of the NHE in ischemic injury was mainly thought to occur during reoxygenation. 7) NHE has been reported to prevent the leukocyte migration that is induced by the chemoattractant agent N-formyl-Met-LeuPhe 31) and the accumulation of leukocytes in infarcted tissue in a myocardial ischemia model. 32) SM-20220 also attenuated leukocyte adhesion to endothelial cells induced by phorbol myristate acetate, a protein kinase C activator. 33) We reported previously that SM-20220 attenuated the accumulation of leukocytes in brain damage induced by MCA occlusion. 34) These results suggest that the activation of NHE may induce leukocyte accumulation in tissues with ischemic damage. Leukocytes play a key role in the acute inflammatory reaction, and the activation of leukocytes is considered to contribute to ischemic brain damage. 35, 36) Matsuo et al. 37) indicated that the amount of leukocyte accumulation in the damaged brain progresses daily, and it is possible that the NHE inhibitor prevented the deterioration caused by post-reperfusion injury by attenuating this accumulation. If SM-20220 is administered at short intervals or by long-term infusion, the effect of multiple administration may become clearer.
In summary, we investigated the effect of SM-20220 on cerebral ischemic injury in a transient MCA occlusion model. SM-20220 reduced the infarct size 22 h after the onset of reperfusion in a dose-dependent manner without altering the systemic arterial blood pressure or blood gas content, and the therapeutic time window for this model was 1 h. Daily administration of SM-20220 did not merely delay but actually reduced infarct size 7 d after reperfusion.
